| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 36,000 | $38.35 | $1,380,720.00 | -20.0% | |
| Feb 26, 2018 | LNTH Lantheus Holdings, Inc. | Healey Timothy G | SVP, Commercial | Sell | 3,696 | $19.58 | $72,358.44 | -5.7% | |
| Feb 23, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 14,802 | $38.15 | $564,664.02 | -21.4% | |
| Feb 23, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 14,802 | $38.15 | $564,664.02 | -21.4% | |
| Feb 21, 2018 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Legal Officer | Sell | 7,741 | $14.66 | $113,483.06 | -2.6% | |
| Feb 21, 2018 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Chief Scientific Officer | Sell | 1,634 | $14.66 | $23,954.44 | -8.3% | |
| Feb 21, 2018 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Commercial Officer | Sell | 3,343 | $14.66 | $49,008.38 | -3.0% | |
| Feb 21, 2018 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | Chief Financial Officer | Sell | 3,594 | $14.66 | $52,688.04 | -2.0% | |
| Feb 21, 2018 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 876 | $77.55 | $67,933.80 | -26.2% | |
| Feb 16, 2018 | ALKS Alkermes Plc. | Stejbach Mark | Svp/ Chief Comm Off, Alks Inc | Sell | 10,880 | $70.50 | $767,092.22 | -19.8% | |
| Feb 15, 2018 | JNJ Johnson & Johnson | Stoffels Paulus | Exec VP, Chief Scientific Off | Sell | 155,342 | $129.86 | $20,172,401.44 | -43.4% | |
| Feb 15, 2018 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 5,000 | $84.67 | $423,341.00 | -1.9% | |
| Feb 15, 2018 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 1,000 | $14.62 | $14,620.00 | -4.4% | |
| Feb 15, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Sabag Mark | EVP, Global Human Resources | Sell | 5,050 | $19.68 | $99,382.50 | -5.5% | |
| Feb 14, 2018 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 17,928 | $35.19 | $630,886.32 | -100% | |
| Feb 13, 2018 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 54,572 | $35.36 | $1,929,548.26 | -100% | |
| Feb 12, 2018 | PBH Prestige Consumer Healthcare Inc. | P'pool William54 | SVP, Gen Counsel &Corp Sec. | Buy | 1,500 | $33.90 | $50,850.00 | +29.4% | |
| Feb 12, 2018 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 86,368 | $78.32 | $6,764,173.36 | -34.2% | |
| Feb 9, 2018 | PAHC Phibro Animal Health Corp | Warras Dean J | Pres Animal Health &Nutr N.a. | Sell | 10,000 | $35.62 | $356,200.00 | -100% | |
| Feb 9, 2018 | MRK Merck & Co., Inc. | Weeks Wendell P62 | Director | Sell | 5,000 | $53.57 | $267,833.00 | -98.0% | |
| Feb 7, 2018 | PBH Prestige Consumer Healthcare Inc. | Ricciardi Natale S | Director | Buy | 3,000 | $37.04 | $111,120.00 | +62.4% | |
| Feb 6, 2018 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 105,983 | $80.25 | $8,504,783.91 | -9.4% | |
| Feb 5, 2018 | PBH Prestige Consumer Healthcare Inc. | Costley Gary E | Director | Buy | 7,500 | $35.47 | $266,025.00 | +24.2% | |
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 2,046 | $83.09 | $169,997.32 | -1.2% | |
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 5,000 | $83.08 | $415,380.00 | -1.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.